Download the Protocol

PEG-MGF

PEG-MGF is a longer-lasting version of the natural repair peptide MGF. It’s designed to help muscles recover and grow after exercise or injury. The “PEG” modification makes it stay active in the body much longer than normal MGF, allowing for less frequent use and steadier recovery effects in research settings.

Description

• PEG-MGF is a modified form of Mechano Growth Factor (MGF), derived from the IGF-1 gene.
• PEG attachment extends the peptide’s half-life, improving stability and circulation time.
• Used in research focused on muscle repair, recovery, and regeneration processes.

How It Works

• Activates satellite cells responsible for muscle repair and regeneration after strain or exercise.
• Stimulates protein synthesis and muscle fiber growth through IGF-1 pathway signaling.
• Pegylation slows down degradation, extending the peptide’s presence in the bloodstream from minutes to hours.

Documented Effects

• Improved muscle recovery and tissue repair in preclinical studies.
• Increased anabolic signaling and protection against muscle cell stress.
• Prolonged half-life compared with standard MGF, allowing for fewer injections.

Theoretical Effects

• Could support steady muscle regeneration over longer recovery periods.
• Potential synergistic use with IGF-1 LR3 or post-training recovery protocols.
• No verified human studies confirming performance or therapeutic benefits.

Pharmacokinetics

• Half-life: Estimated 24–36 hours (significantly longer than MGF).
• Peak activity: Within several hours post-administration.
• Elimination: Slow clearance due to PEG chain modification.

Reconstitution

• Use bacteriostatic water for reconstitution.
• Example vial: 2 mg PEG-MGF
• Choose reconstitution volume based on dosing preference:
  • 1 mL → 0.2 mg (200 mcg) per 10 units
  • 2 mL → 0.1 mg (100 mcg) per 10 units
• Swirl gently to dissolve; do not shake.
• Refrigerate reconstituted solution (2–8 °C). Use within ~30 days for best stability.

Injectable Dosage Overview (Research Reference)

Typical Starting Dose

• 200–300 mcg subcutaneous (SC) or intramuscular (IM) 2–3× per week.
• Less frequent dosing than standard MGF due to prolonged activity.

Common Research Range

• 200–400 mcg SC or IM 2–3× weekly, usually following exercise or localized muscle stress.
• Sometimes alternated with unmodified MGF to mimic natural acute and extended signaling.

Maximum Weekly Dose

• Typically does not exceed 1–2 mg total per week.
• Higher or daily dosing may decrease receptor sensitivity over time.

Standard Cycle Length

• Short cycle: 4–6 weeks of continuous use.
• Extended research cycles: 8 weeks on, 4 weeks off for receptor reset.

Clinical Notes

• PEGylated MGF provides a prolonged biological half-life compared to standard MGF, allowing less frequent dosing.
• Commonly administered subcutaneously; avoid injecting directly into muscle groups that were intensely trained that same day.
• Best used post-workout or on rest days to support recovery and satellite-cell activation.
• May cause mild localized swelling, warmth, or temporary fatigue as part of growth-factor signaling.
• Because PEG-MGF has a long active window, daily dosing is unnecessary; 2–3× weekly is typical.
• Stable for about 30 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes

• Limited to laboratory and animal research; no verified human trials.
• Ensure compound authenticity and sterile handling during preparation.
• Pegylated peptides may increase immune sensitivity or injection site irritation in some models.
• Not approved for human or therapeutic use.